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Conclusions: No significant relationship between the mean 
dose to the salivary apparatus and subjective xerostomia was 
observed. However, this study did show that despite 
undergoing parotid sparing IMRT, a large number of patients 
still display a high degree of symptomology for years after 
treatment, but these symptoms do not appear to have a 
deleterious effect on quality of life in survivors. Patients’ 
perceptions are subject to change after a diagnosis of H&N 
cancer. This study strongly suggests that a psychological 
adjustment of patients to their symptoms and a redefinition 
of their expectations is possible.  
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Recently the first replicated genetic associations and GWAS 
for adverse reactions to radiotherapy have been reported. 
These will help to build predictive statistical models for 
optimising radiotherapy delivery or interventions to alleviate 
the side effects. It is now important to validate known 
predictors of adverse reactions and develop the statistical 
models to become clinically useful. The REQUITE project is a 
European Union funded FP7 project that aims to do this. 
REQUITE’s objectives: 
1. Perform a multi-centre, cohort study collecting: blood 
samples, epidemiology and treatment data, longitudinal side-
effect and QOL data (before and after treatment, years 1 & 
2). 
2. Produce a centralised biobank of DNA from 5,300 patients 
with centralised data management. 
3. Validate published biomarkers of radiosensitivity. 
4. Validate clinical predictors of radiotherapy toxicity in 
breast, prostate and lung cancer and incorporate biomarker 
data. 
5. Design interventional trials to reduce long-term side-
effects. 
6. Provide a resource for dissemination and exploitation to 
the radiotherapy community. 
REQUITE is funded for 60 months from October 2013 and 
organised into seven work packages. WP1 is responsible for 
overall management and scientific oversight run by 
Manchester. The central activity of the project is a multi-
centre, observational study organised through WP2, led by 
DKFZ. Enrolment began in April 2014 and will proceed for 2 
years in nine clinical centres, with 2 years follow-up. Current 
recruitment has exceeded 500 patients. The primary 
endpoints are change in breast appearance; rectal bleeding 
(prostate); pneumonitis (lung). The integrated database has 
been designed at Leicester. 
Blood samples are being collected before radiotherapy. 
Tracking, biobanking and DNA preparation is handled in WP3 
at CIGMR in Manchester. Validation of biomarkers (genetic 
markers and apoptosis assays) as predictive factors is being 
carried out in WP4 led by Leicester. Preliminary work has 
reduced inter-laboratory variation in the FACS-based 
apoptosis assay between Leicester, Mannheim and 
Montpellier. The assay is now being carried out on all samples 
collected through the three centres. The data will establish 
whether the assay can be used as a standard test to predict 
radiotherapy toxicity. 
In WP5 Gent is leading in validating published models in 
existing cohorts, leading to replicated models that can be 
validated using the REQUITE cohorts. In WP6 Leuven will use 
the predictive models to design clinical interventional trials 
and produce protocols that seek to lower radiotherapy side-
effects in those individuals at high risk of developing them 
without affecting tumour control. Dissemination and 
Outreach is being co-ordinated through WP7 led by MAASTRO. 
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Biomarkers of normal tissue toxicity are used in determining 
predictive models of toxicity and may help understanding of 
the biology of radiation response in normal tissue. 
Whilst clinical assessment of toxicity has been evaluated 
quantitatively, this often encompasses complex clinical 
endpoints, incorporating different pathological entities. 
Other quantitative assessments of normal tissue effects 
which may more directly reflect underlying pathological 
alterations in tissue include imaging at the anatomical or 
functional level, and measurement of cell or molecular 
alterations in blood or tissue. These approaches may improve 
descriptive radiobiology or the characterization of late 
normal tissue effects. 
